Soluble urokinase receptor released from human carcinoma cells: A plasma parameter for xenograft tumour studies

British Journal of Cancer

Volumn 81, Issue 2, 1999, Pages 203-211

  Holst Hansen, C ^a   Hamers, M J A G ^a   Johannessen, B E ^a   Brunner N ^a   Stephens, R W ^a  

^a FINSEN LABORATORY   (Denmark)

Author keywords

Human cancer xenografts; Soluble receptor; uPAR

Indexed keywords

UROKINASE RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; BLOOD LEVEL; BREAST CARCINOMA; CANCER INVASION; CANCER PATIENT; CARCINOMA CELL; CELL CULTURE; CELL GROWTH; CELL LYSATE; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; METASTASIS; MOUSE; NONHUMAN; NORTHERN BLOTTING; PLASMINOGEN ACTIVATION; PRIORITY JOURNAL; PROTEIN DOMAIN; TUMOR VOLUME; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 0032855119     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690678     Document Type: Article

References (43)

1. Andreasen PA, Kjøller L, Christensen I. and Duffy MJ (1997) The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72: 1-22
2. Baramova EN, Bajou K, Remacle A, Lhoir C, Krell HW, Weidle UH, Nöel A and Foidart JM (1997) Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405: 157-162
3. Behrendt N, Ronne E, Ploug M, Petri T, Lober D, Nielsen LS, Schleuning WD, Blasi F. Appelle F. and Danø K (1990) The human receptor for urokinase plasminogen activator. NH2-terminal amino acid sequence and glycosylation variants. J Biol Chem 265: 6453-6460
4. Brünner N, Thompson EW, Spang-Thomsen M, Rygaard J, Danø K and Zwiebel JA (1992) lacZ transduced human breast cancer xenografts as an in vivo model for the study of invasion and metastasis. Eur J Cancer 28A: 1989-1995
5. Chavakis T, Kanse SM, Yutzy B, Lijnen HR and Preissner KT (1998) Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor urokinase complexes. Blood 91: 2305-2312
6. Chomezynski P and Sacchi N (1987) Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162: 156-159
7. Danø K, Andreasen PA, Grøndahl-Hansen J, Kristensen P, Nielsen LS and Skriver L (1985) Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44: 139-266
8. Danø K, Behrendt N, Brünner N, Ellis V, Ploug M and Pyke C (1994) The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 8: 189-203
9. Deng G, Curriden SA, Wang SJ, Rosenberg S and Loskutoff DJ (1996) Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release. J Cell Biol 134: 1563-1571
10. Ellis V, Behrendt N and Danø K (1991) Plasminogen activation by receptor-bound urokinase. A kinetic study with both cell-associated and isolated receptor. J Biol Chem 266: 12752-12758
11. Femberg AP and Vogelstem B (1983) A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. Anal Biochem 132: 6-13
12. Ganesh S, Sier CF, Heerding MM, Griffioen G, Lamers CB and Verspaget HW (1994) Urokinase receptor and colorectal cancer survival. Lancet 344: 401-402
13. Gineslra A, Monea S, Seghezzi G, Dolo V, Nagase H, Mignatti P and Vittorelli ML (1997) Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem 272: 17216-17222
14. Grøndahl-Hansen J, Peters HA, Van PW, Look MP, Pappot H, Rønne E, Danø K, Klijn JM, Brünner N and Fockens JA (1995) Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Can Res 1079-1087
15. He CS, Wilhelm SM, Pentland AP, Marmer BL, Grant GA, Eisen AZ and Goldberg GI (1989) Tissue cooperation in a proteolytic cascade activating human interslitial collagenase. Proc Natl Acad Sci USA 86: 2632-2636
16. Holst-Hansen C, Johannessen B, Høyer-Hansen G, Rømer J, Ellis V and Brünner N (1996) Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness. Clin Exp Metastasis 14: 297-307
17. Høyer-Hansen G, Behrendt N, Ploug M, Danø K and Preissner KT (1997) The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420; 79-85
18. Lau HK and Kim M (1994) Soluble urokinase receptor from fibrosarcoma HT-1080 cells. Blood Coagul Fibrinolysis 5: 473-478
19. Lyons RM, Gentry LF, Purchio AF and Moses HL (1990) Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 110: 1361-1367
20. Masucci MT, Pedersen N and Blasi F (1991) A soluble, ligand binding mutant of the human urokinase plasminogen activator receptor. J Biol Chem 266: 8655-8658
21. Pappot H, Høyer-Hansen G, Rønne E, Hansen HH, Brünner N, Danø K and Grøndahl-Hansen J (1997) Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients. Eur J Cancer 33: 867-872
22. Pedersen N, Schmitt M, Rønne E, Nicoletti MI, Høyer-Hansen G, Conese M, Giavazzi R, Danø K, Kuhn W, Jänicke F and Blasi F (1993) A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer. J Clin Invest 92: 2160-2167
23. Pedersen H, Brünner N, Francis D, Østerlind K, Ronne E, Hansen HH, Danø K and Grøndahl Hansen J (1994) Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. Cancer Res 54: 4671-4675
24. Plesner T, Behrendt N and Ploug M (1997) Structure, function and expression on blood and bone marrow cells of the urokinase-type plasminogen activator receptor, uPAR. Stem Cells 15: 398-408
25. Ploug M, Rønne E, Behrendt N, Jensen AL, Blasi F and Danø K (1991) Cellular receptor for urokinase plasminogen activator. Carboxyl-terminal processing and membrane anchoring by glycosyl-phosphatidylinositol. J Biol Chem 266: 1926-1933
26. Ploug M, Ellis V and Danø K (1994) Ligand interaction between urokinase-type plasminogen activator and its receptor probed with 8-anilino-1-naphthalenesulfonate. Evidence for a hydrophobic binding site exposed only on the intact receptor, Biochemistry 33: 8991-8997
27. Ploug M, Østergaard S, Hansen LBL, Holm A and Danø K (1998) Photoaffinity labeling of the human receptor for urokinase-type plasminogen activator using a decapeptide antagonist. Evidence for a composite ligand-binding site and a short interdomain separation. Biochemistry 37: 3612-3622
28. Ponte P, Ng SY, Engel J, Gunning P and Kedes L (1984) Evolutionary conservation in the untranslated regions of actin mRNAs; DNA sequence of a human beta-actin cDNA. Nucleic Acids Res 12: 1687-1696
29. Pyke C, Kristensen P, Ralfkiaer E, Grøndahl-Hansen J, Eriksen J, Blasi F and Danø K (1991) Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. Am J Pathol 138: 1059-1067
30. Pyke C, Graem N, Ralfkiaer F, Rømer J, Høyer Hansen G, Brünner N and Danø K (1993) Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res 15: 1911-1915
31. Resnati M, Guttinger M, Valcamonica S, Sidenius N, Blasi F and Fazioli F (1996) Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582
32. Roldan AL, Cubellis MV, Masucci MT, Behrendt N, Lund LR, Danø K, Appella E and Blasi F (1990) Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474
33. Rømer J, Pyke C, Lund LR, Eriksen J, Kristensen P, Rønne E, Høyer Hansen G, Danø K and Brünner N (1994) Expression of uPA and its receptor by both neoplastic and stromal cells during xenograft invasion. Int J Cancer 57: 553-560
34. Rønne E, Behrendt N, Ploug M, Nielsen HJ, Wollisch E, Weidle U, Danøo K and Høyer-Hansen G (1994) Quantitation of the receptor for urokinase plasminogen activator by enzyme-linked linked immunosorbent assay. J Immunol Methods 167: 91-101
35. Rønne E, Høyer-Hansen G, Brünner N, Pedersen H, Rank F, Osborne CK, Clark GM, Danø K and Grøndahl-Hansen J (1995a) Urokinase receptor in breast cancer tissue extracts. Enzyme-linked immunosorbent assay with a combination of mono- and polyclonal antibodies. Breast Cancer Res Treat 33: 199-207
36. Rønne E, Pappot H, Grøndahl-Hansen J, Høyer-Hansen G, Plesner T, Hansen NE and Danø K (1995b) The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 89: 576-581
37. Shapiro RL, Duquetle JG, Roses DF, Nunes I, Harris MN, Kamino H, Wilson EL and Rifkin DB (1996) Induction of primary cutaneous melanocytic neoplasms in urokinase-type plasminogen activator (uPA)-deficient and wild-type mice -cellular blue nevi invade but do not progress to malignant melanoma in uPA-deficient animals. Cancer Res 56: 3597-3604
38. Sier CFM, Stephens RW, Bizik J, Mariani A, Bassan M, Pedersen N, Frigerio L, Ferrari A, Danø K, Brünner N and Blasi F (1998) The level of urokinase plasminogen activator receptor (uPAR) is increased in serum of ovarian cancer patients. Cancer Res 58: 1843-1849
39. Solberg H, Rømer J, Brünner N, Holm A, Sidenius N, Danø K and Høyer-Hansen G (1994) A cleaved form of the receptor for urokinase-type plasminogen activator in invasive transplanted human and murine tumors. Int J Cancer 58: 877-881
40. Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJ, Høyer-Hansen G, Rønne E, Dybkjær E, Danø K and Brünner N (1997) ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 43: 1868-1876
41. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K and Brünner N (1999) Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869-874
42. Wilhelm O, Weidle U, Hohl S, Rettenberger P, Schmitt M and Graeff H (1994) Recombinant soluble urokinase receptor as a scavenger for urokinase-type plasminogen activator (uPA). Inhibition of proliferation and invasion of human ovarian cancer cells. FEBS Lett 337: 131-134
43. Wohn KD, Kanse SM, Deutsch V, Schmidt T, Eldor A and Preissner KT (1997) The urokinase-receptor (CD87) is expressed in cells of the megakaryoblastic lineage. Thromb Haemost 77: 540-547